Overview : BSI-060T is a humanized anti-Siglec-15 monoclonal antibody which demonstrated 6-fold higher affinity to human Siglec-15 and higher ex vivo efficacy than NC-318 which is in Phase 2 development. Siglec-15 is an immune suppressor and potential target for normalization cancer immunotherapy, it is upregulated in multiple solid tumors, including NSCLC, head and neck cancer, thyroid cancers. In Mar 2022, Biosion licensed ex-Greater China rights of BSI-060T to Pyxis Oncology and retains all rights for development and commercialization in Greater China.

Development status : Pyxis Oncology plans to file an IND in the US and Biosion plans to file an IND in China filing 2H 2022.